Merck Long-Term Investments 2010-2024 | MRK
Merck long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
- Merck long-term investments for the quarter ending June 30, 2024 were $0.357B, a 70.59% decline year-over-year.
- Merck long-term investments for 2023 were $0.252B, a 75.17% decline from 2022.
- Merck long-term investments for 2022 were $1.015B, a 174.32% increase from 2021.
- Merck long-term investments for 2021 were $0.37B, a 52.87% decline from 2020.
Merck Annual Long-Term Investments
(Millions of US $) |
| 2023 |
$252 |
| 2022 |
$1,015 |
| 2021 |
$370 |
| 2020 |
$785 |
| 2019 |
$1,469 |
| 2018 |
$6,233 |
| 2017 |
$12,125 |
| 2016 |
$11,416 |
| 2015 |
$13,039 |
| 2014 |
$13,515 |
| 2013 |
$9,770 |
| 2012 |
$7,305 |
| 2011 |
$3,458 |
| 2010 |
$2,175 |
| 2009 |
$432 |
Merck Quarterly Long-Term Investments
(Millions of US $) |
| 2024-06-30 |
$357 |
| 2024-03-31 |
$280 |
| 2023-12-31 |
$252 |
| 2023-09-30 |
$1,306 |
| 2023-06-30 |
$1,214 |
| 2023-03-31 |
$1,290 |
| 2022-12-31 |
$1,015 |
| 2022-09-30 |
$984 |
| 2022-06-30 |
$238 |
| 2022-03-31 |
$316 |
| 2021-12-31 |
$370 |
| 2021-09-30 |
$435 |
| 2021-06-30 |
$411 |
| 2021-03-31 |
$544 |
| 2020-12-31 |
$785 |
| 2020-09-30 |
$1,372 |
| 2020-06-30 |
$1,251 |
| 2020-03-31 |
$555 |
| 2019-12-31 |
$1,469 |
| 2019-09-30 |
$2,111 |
| 2019-06-30 |
$3,779 |
| 2019-03-31 |
$5,621 |
| 2018-12-31 |
$6,233 |
| 2018-09-30 |
$7,606 |
| 2018-06-30 |
$10,033 |
| 2018-03-31 |
$11,033 |
| 2017-12-31 |
$12,125 |
| 2017-09-30 |
$12,206 |
| 2017-06-30 |
$12,138 |
| 2017-03-31 |
$11,896 |
| 2016-12-31 |
$11,416 |
| 2016-09-30 |
$11,657 |
| 2016-06-30 |
$11,879 |
| 2016-03-31 |
$12,554 |
| 2015-12-31 |
$13,039 |
| 2015-09-30 |
$13,080 |
| 2015-06-30 |
$13,333 |
| 2015-03-31 |
$13,092 |
| 2014-12-31 |
$13,515 |
| 2014-09-30 |
$13,492 |
| 2014-06-30 |
$12,618 |
| 2014-03-31 |
$11,456 |
| 2013-12-31 |
$9,770 |
| 2013-09-30 |
$9,198 |
| 2013-06-30 |
$8,555 |
| 2013-03-31 |
$7,948 |
| 2012-12-31 |
$7,305 |
| 2012-09-30 |
$5,560 |
| 2012-06-30 |
$4,085 |
| 2012-03-31 |
$3,972 |
| 2011-12-31 |
$3,458 |
| 2011-09-30 |
$2,423 |
| 2011-06-30 |
$2,175 |
| 2011-03-31 |
$2,084 |
| 2010-12-31 |
$2,175 |
| 2010-09-30 |
$2,138 |
| 2010-06-30 |
$2,046 |
| 2010-03-31 |
$1,995 |
| 2009-12-31 |
$432 |
| 2009-09-30 |
$465 |
| 2009-06-30 |
$110 |
| 2009-03-31 |
$79 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$300.492B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
